NASDAQ:CNAT - Conatus Pharmaceuticals Inc.
$0.31
 $-0.01
-4.53%
12:05PM EDT
2019-07-22
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  CNAT     avg for
industry  
  avg for
sector  
42 stocks weight:  1. 59   217. 37   399. 45  
42 stocks rank:  4. 45 K 1. 27 K 716. 99  
# analyst opinions:  2. 00   13. 21   13. 71  
mean recommendation:  3. 00   2. 10   2. 04  

quick ratio:  2. 25   5. 49   1. 88  
current ratio:  2. 40   5. 87   2. 36  

target price low:  0. 48   83. 44   114. 90  
target price avg:  0. 51   106. 20   137. 90  
target price high:  0. 54   132. 30   158. 97  
1-yr high:  6. 49   111. 86   142. 57  
last close:  0. 32   86. 79   125. 44  
50-day avg:  0. 65   86. 68   122. 63  
200-day avg:  2. 11   89. 22   121. 38  
1-yr low:  0. 26   69. 78   100. 51  
volume:  431. 08 K 2. 62 M 3. 43 M
50-day avg volume:  1. 00 M 3. 20 M 4. 16 M
200-day avg volume:  928. 93 K 2. 99 M 4. 75 M

1-day return:  -2. 39 % -1. 30 % -0. 99 %
this week return:  -5. 87 % 0. 45 % -0. 20 %
12-wk return:  -58. 17 % 0. 94 % 4. 84 %
52-wk return:  -92. 25 % -1. 30 % 10. 55 %

enterprise value (EV):  -22. 52 M 45. 10 B 122. 38 B
market cap:  10. 68 M 38. 96 B 108. 40 B
EBITDA:  -18. 09 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  1. 25   5. 38   11. 93  
enterprise/revenue (EV/R):  -0. 73   57. 92   10. 21  
total revenue:  30. 87 M 9. 91 B 39. 98 B
total debt:  627. 00 K 10. 90 B 17. 48 B
debt/equity:  2. 66   57. 18   120. 05  
net income (common):  -17. 74 M 2. 07 B 4. 05 B

shares outstanding:  33. 17 M 538. 09 M 1. 24 B
shares:  29. 86 M 548. 00 M 1. 22 B
shares short:  2. 78 M 10. 98 M 11. 87 M
shares short prior month:  3. 55 M 9. 32 M 12. 05 M
short ratio:  2. 56   5. 60   3. 34  
short % of float:  8. 85 % 6. 48 % 2. 64 %
total cash/share:  1. 02   10. 98   9. 19  
total cash:  33. 83 M 5. 93 B 6. 10 B
free cash flow:  -21. 61 M 2. 92 B 4. 55 B
operating cash flow:  -33. 67 M 3. 80 B 5. 78 B

book value:  0. 71   13. 35   27. 45  
price/book:  0. 45   4. 60   8. 78  
gross profits:  -7. 78 M 7. 44 B 36. 13 B
operating margins:  -58. 85 % -308. 40 % -28. 55 %
EBITDA margins:  -58. 58 % 13. 17 % 23. 38 %
profit margins:  -57. 46 % 10. 44 % 14. 18 %
gross margins:  -25. 25 % 35. 80 % 55. 40 %

1-yr max volatility:  0. 00 % --- ---
1-yr mean volatility:  0. 00 % 1. 66 % 1. 03 %

1-yr EPS:  -0. 57   2. 10   4. 23  
forward EPS:  -0. 25   3. 45   7. 10  
P/E:  -0. 57   1. 90   32. 10  
forward P/E:  -1. 29   6. 46   15. 47  
PE/G:  0. 02   0. 70   -0. 54  
growth:  -27. 90 % 265. 63 % 79. 11 %
earnings high:  -0. 12   0. 89   1. 68  
earnings avg:  -0. 12   0. 70   1. 57  
earnings low:  -0. 12   0. 46   1. 46  
revenue high:  7. 00 M 2. 57 B 11. 07 B
revenue avg:  7. 00 M 2. 51 B 10. 91 B
revenue low:  7. 00 M 2. 45 B 10. 73 B
return on assets:  -19. 11 % -2. 34 % 5. 28 %
return on equity:  -75. 57 % -90. 08 % 133. 53 %
revenue growth:  -27. 90 % 265. 25 % 73. 68 %
revenue/share:  0. 99   12. 72   60. 04  

beta (1yr vs S&P500):  3. 18   1. 27   0. 91  
sharpe (1yr):  -0. 61   0. 16   0. 77  

held % insiders:  3. 34 % 6. 06 % 3. 29 %
held % institutions:  24. 84 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : CNAT
.    100.697 =       100.697 :: --> INITIAL WEIGHT <--
.    - 0.569 =       100.128 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.958 =       196.022 :: P/E factor
.    x 2.209 =       433.004 :: PE/G factor
.    x 1.174 =       508.188 :: beta factor
.     x 0.86 =       436.803 :: sharpe factor
.     x 2.41 =      1052.556 :: current ratio factor
.    x 1.342 =      1412.907 :: quick ratio factor
.    x 1.179 =      1666.167 :: short ratio factor
.    x 1.002 =      1669.932 :: price-to-book factor
.    x 4.434 =      7404.686 :: EBITDA factor
.     x 1.11 =      8216.692 :: EBITDA vs industry factor
.    x 5.564 =     45715.602 :: debt-to-revenue factor
.    x 1.023 =     46765.644 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =     99180.253 :: sector+industry 1-year gains factor
.    x 1.009 =     100115.33 :: industry 12-weeks return factor
.    x 1.308 =    130939.698 :: industry 2-weeks return factor
.    / 2.349 =      55732.85 :: overall "drift" factor
.      x 0.0 =        23.408 :: largest single-day jump factor
.    x 0.059 =         1.389 :: low price factor
.      x 0.0 =           0.0 :: notable returns + performance factor
.    x 0.002 =           0.0 :: performance vs s&p500 factor
.                               --> PROJECTIONS <--
.    x 0.062 =           0.0 :: forward EPS factor
.    x 0.659 =           0.0 :: forward P/E factor
.    x 1.185 =           0.0 :: industry recommendation factor
.     x 1.66 =           0.0 :: company recommendation factor
.    x 1.003 =           0.0 :: factor historical industry gain for week 29
.    x 1.862 =           0.0 :: target low factor
.    x 1.254 =           0.0 :: target mean factor
.    x 1.035 =           0.0 :: target high factor
.   x 10.201 =           0.0 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.    + 1.593 =         1.593 :: add/subtract for investor sentiment
.                               --> FINAL WEIGHT <--
.                      1.593 :: FINAL WEIGHT for NASDAQ:CNAT


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org